In February 2025, Gan & Lee Pharmaceuticals (hereafter referred to as "Gan & Lee," stock code: 603087.SH) unveiled that the first participant was successfully dosed in a large-scale Phase 3 clinical trial (OPTIMUM-2) of Bofanglutide, a bi-weekly glucagon-like peptide-1 receptor agonist (GLP-1RA) independently, in Chinese participant with type 2 diabetes mellitus (T2DM)
These findings suggest that part of the clinical benefit of GLP-1RAs in PsO may derive not only from metabolic improvements but also from direct modulation of adipose-driven inflammatory pathways
If the reaction worsens over six weeks rather than improving, the problem is not the copper uglies
According to the Wegovy SmPC, if pancreatitis is suspected, semaglutide should be discontinued immediately and urgent medical assessment sought
During open enrollment season, workers could look to GLP-1 coverage to determine what plan to enroll in
Are oral or sublingual GLP-1 formulations better for dry mouth
:max_bytes(150000):strip_icc()/benefits-of-glutathione-89457_final-01-502464fe91b2444285b0cccf8cb0a33c.png)
